Of the public speakers at Anesthetic and Analgesic Drug Products Advisory Committee meetings, about 20% had undisclosed conflicts of interest and those who did have conflicts of interest were much more likely to support drug approvals, according to findings published in JAMA Internal Medicine.
“Little formal attention ... has been paid to the possibility of such conflicts of interest among patients and advocates who appear as public speakers before the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), which advises the FDA on drug products used in anesthesiology and
Uncategorized